Panobinostat is an oral pan-histone deacetylase inhibitor developed by Novartis. Panobinostat 
INTRODUCTION
Multiple myeloma (MM) is a hematologic disorder characterized by clonal proliferation of malignant plasma cells in the bone marrow that overproduce abnormal monoclonal proteins [1] . It can be classified as asymptomatic or active, based on the presence of MM biomarkers (clonal bone marrow plasma cells, serum free light chain ratio, and focal lesions) or CRAB criteria (disease-associated organ damage that includes hypercalcemia, renal insufficiency, anemia, and bone disease) [2] . MM tends to present in older patients, with the median age at diagnosis being &70 years [1] . Therefore, the incidence of MM is expected to increase as the population ages, as seen in a recent European survey [3] . In this survey, there were &39,000 cases of newly diagnosed MM in 2012 [4] , with the incidence expected to rise by 30% by 2035 [3] .
MM remains an incurable disease. Over the past decade, breakthroughs in myeloma therapy, particularly the introduction of proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) and the use of autologous stem cell transplantation, have vastly improved patient outcomes [5, 6] .
However, due to the clonal nature of the disease, the majority of patients will relapse after currently available therapies, and with each successive relapse, the prognosis worsens [7, 8] . Therefore, an unmet need exists for agents with new mechanisms of action that can overcome disease resistance to current therapeutic regimens.
Panobinostat, a first-in-class pan-deacetylase inhibitor (DACi), was recently authorized by the European Commission (EC) and recommended by the National Institute for Health and Care Excellence (NICE) in combination with bortezomib and dexamethasone for the treatment of patients with MM who have received C2 prior therapeutic regimens including bortezomib and an IMiD. This review will discuss the current treatment landscape for relapsed/refractory MM (RRMM), the unique mechanism of action of panobinostat, clinical data supporting the EC authorization of panobinostat in patients with relapsed or RRMM who have received C2 prior therapeutic regimens, concerns about safety and strategies for mitigating toxicity, and how this novel therapeutic fits into the current MM treatment landscape in Europe.
Compliance with Ethics Guidelines
This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
TREATMENT OF RRMM IN EUROPE: THE CURRENT THERAPEUTIC LANDSCAPE
Although, as mentioned, major advances have been made in the treatment of patients with MM [5, 8] , the majority of patients will eventually relapse after or become refractory to the available therapies [7, 8] . However, the majority of agents currently authorized by the EC for the treatment of MM are derived from just two drug classes, PIs and IMiDs (Table 1 ). (April 16, 2008) , and pomalidomide (August 5, 2013); however, thalidomide is authorized only in patients with untreated myeloma [9] . Other agents include classical chemotherapeutics, such as doxorubicin, cyclophosphamide, and bendamustine-as possible salvage therapies or in combination with novel agents-as well as 
PIs
It is believed that MM cells are much more sensitive to proteasome inhibition than normal cells due to the aberrant production of abnormal and mutant proteins [10] . Blockade of the proteasome leads not only to an unfolded protein stress response within the cell [11] , but can also directly influence expression of proteins normally degraded through active proteasomes, including those involved in apoptosis, cell cycle progression, and activation of the transcriptional factor NFjB. Therefore, inhibiting the proteasome can lead to apoptosis and inhibition of proliferation [12, 13] .
Bortezomib
Bortezomib was the first PI to be authorized for the treatment of MM by the EC (Table 1) .
Bortezomib is a boronic acid analog that reversibly binds and inhibits the chymotryptic activity of the 20S proteasome subunit [14] . In the phase 3 APEX trial (NCT00048230), bortezomib was superior to dexamethasone for the treatment of MM that had relapsed after 1-3 previous therapies (Table 2 ) [15] . Patients treated with bortezomib had a significant increase in overall response rate (ORR; 38% vs 18%; P\0.001), a significantly prolonged time to progression (TTP; 6.2 vs 3.5 months; P\0.001), and a significant overall survival (OS) benefit (80% vs 66% at 1 year; P = 0.003) ( Table 2) .
Carfilzomib
Carfilzomib, a second-generation PI, is a tetrapeptide epoxyketone analog of epoxomicin that primarily inhibits the chymotrypsin site of the 20S subunit of the proteasome but may also act upon the trypsin-like and caspase-like sites at high concentrations [12, 16] . Carfilzomib binds Based on these promising findings, two large randomized phase 3 studies were initiated, one in North America (MM-009; NCT00056160) [26] and one in Europe, Australia, and Israel (MM-010; NCT00424047) [27] . These studies assessed the combination of lenalidomide plus dexamethasone vs placebo plus dexamethasone in patients with RRMM who had received C1 prior therapy ( Pomalidomide is also being evaluated in combination with low-dose dexamethasone and bortezomib. This combination showed promising activity (ORR, 71%) and good tolerability in a phase 1 dose-escalation study in patients with RRMM [35] and is now being assessed in the global, randomized, phase 3 MM-007 study (OPTIMISMM; NCT01734928) [36] . MM-007 is designed to compare pomalidomide plus bortezomib plus low-dose dexamethasone vs bortezomib plus dexamethasone in patients with RRMM who have received 1-3 prior lines of therapy, including lenalidomide (target enrollment 782). The primary endpoint will be PFS.
Monoclonal Antibodies
Monoclonal antibodies have shown antitumor activity in a variety of cancers. Patients who had received C1 prior line of therapy were randomized 1:1 to receive either daratumumab-bortezomib-dexamethasone (n = 251) or bortezomib-dexamethasone (n = 247). Daratumumab plus bortezomib significantly improved median PFS, the primary endpoint, leading to a 61% reduction in the risk of progression or death vs bortezomib alone (P\0.0001). In addition, daratumumab increased the TTP (not reached vs 7.3 months; P\0.0001) as well as the ORR (83% vs 63%; P\0.0001). The safety profile of the combination therapy was consistent with that of daratumumab and bortezomib, with thrombocytopenia, anemia, and neutropenia being the most common grade 3/4 AEs.
Novel Agents
As MM therapy continues to evolve at a rapid pace, a number of new agents are in clinical development. These agents include the first oral proteasome inhibitor (ixazomib) and a novel monoclonal antibody targeting CD38
(isatuximab). [57] . Preliminary reports from a second phase 1 study (NCT01749969; n = 12)
found that the efficacy of isatuximab was enhanced when given in combination with lenalidomide and dexamethasone (ORR 58%) [58] . Additionally, a preclinical study showed that pomalidomide increased isatuximab-induced MM cell killing, and that it did so more potently than lenalidomide [59] .
Furthermore, enhanced antitumor activity has been demonstrated with isatuximab plus bortezomib in preclinical models [60] . Several preclinical studies have shown that DACi are active in MM. One study showed that a DACi (panobinostat) reactivated genes repressed by the hypermethylation of H3K27 by the Polycomb group proteins and reduced proliferation and increased apoptosis in human MM cell lines [64] . Additionally, panobinostat led to gene upregulation, reduction of tumor load, and increased OS in preclinical models [64] . Likewise, upregulation of genes following treatment of MM cell lines with DACi correlated with increased OS [67] . Interestingly, the antimyeloma activity of DACi was found to occur largely through inhibition of HDAC1, an event necessary for maximal MM cell death [68] .
Based on these and other preclinical (Fig. 1b) . (Fig. 2) . Similarly, patients who had received C2 prior regimens including bortezomib and an IMiD had a higher ORR with panobinostat than with placebo (59% vs 39%; P = 0.01703) ( Overall, the safety profile in this subgroup was similar to that in the overall PANORAMA 1 population (Table 4) The proportion of on-treatment deaths was similar between the two treatment groups among patients who received C2 prior regimens including bortezomib and an IMiD (panobinostat, 6.9%; placebo, 6.8%) [80] .
Deaths due to progressive disease among patients in this group were slightly higher in the placebo group (panobinostat, 0%; placebo, 2.7%). The proportion of on-treatment deaths was slightly higher in the panobinostat group of the overall PANORAMA 1 population than in the placebo group or the subgroup of patients who received C2 prior regimens including bortezomib and an IMiD [79, 80] . The proportion of deaths due to progressive disease in the overall population was similar to that observed in the heavily pretreated subgroup. (Fig. 3 ).
Concerns were raised during the authorization process about the safety and tolerability of the panobinostat-bortezomib-dexamethasone regimen, and thus a risk management plan was devised to ensure that the regimen was provided as safely as possible and included guidance for management of key AEs [83] . On balance is advised [87] .
Physicians should manage grade 2 diarrhea (4-6 stools/day above baseline) with Other Notable AEs Patients at risk of infection should be treated prior to receiving the regimen [87] . White blood cell counts should be monitored regularly, and any developing infection should be treated promptly [87] .
Panobinostat therapy should be avoided in patients at risk for QTc prolongation or receiving concomitant medications known to prolong the QT interval that cannot be stopped [87] 
